ArticleBMC urology2025
An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer-the EXUROC prostate study, a clinical trial protocol.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06480110 (Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis clinical trial investigates the addition of a repurposed drug, the cationic amphiphilic drug (CAD) ebastine, to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Preclinical data have shown that chemotherapy-resistant prostate cancer cells can be re-sensitized and that combining CAD with docetaxel significantly inhibits tumor growth in xenograft mouse models of docetaxel-resistant mCRPC. The primary objective of this study is to evaluate the impact of ebastine plus docetaxel versus docetaxel alone for mCRPC, measured as Bis(monoacylglycero)phosphate (BMP) and lysophospholipids in urine and blood. Secondary endpoints are prostate-specific antigen (PSA) and radiologic progression-free survival.
methodsThis randomized, open-label, phase ll trial will include 30 patients with disease progression after prior therapy for mCRPC, in a 2:1 ratio favoring the intervention arm. Inclusion criteria are metastatic adenocarcinoma/poorly differentiated carcinoma of the prostate, serum testosterone levels ≤ 50 ng/dL., and that patients are planned for docetaxel treatment. DISCUSSION: The trial was initiated on 1 June 2024 and is currently recruiting participants. Results are expected to be available by Q4 2027. This phase II study aims to evaluate the clinical effectiveness of CADs, with a specific focus on biomarkers such as BMP and lysophospholipids. This biomarker-driven approach offers a unique opportunity to gain insight into the biological effects of the combination treatment, particularly its impact on lysosomal lipid metabolism. If the biological rationale is confirmed, the study will proceed to a phase II/III large-scale randomized trial.
trial registrationThe trial is registered on ClinicalTrials.gov as NCT06480110.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.